FUSION PHARMACEUTICALS INC's ticker is FUSN and the CUSIP is 36118A100. A total of 35 filers reported holding FUSION PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $431,756 | -32.8% | 166,060 | +20.7% | 0.00% | – |
| Q2 2023 | $642,643 | +44.2% | 137,611 | +16.4% | 0.00% | – |
| Q1 2023 | $445,746 | +31.1% | 118,235 | +9.5% | 0.00% | – |
| Q4 2022 | $340,036 | +47.2% | 107,948 | +40.8% | 0.00% | – |
| Q3 2022 | $231,000 | +58.2% | 76,677 | +30.4% | 0.00% | – |
| Q2 2022 | $146,000 | -81.9% | 58,822 | -43.4% | 0.00% | – |
| Q1 2022 | $808,000 | +149.4% | 103,982 | +34.0% | 0.00% | – |
| Q4 2021 | $324,000 | -50.2% | 77,609 | -5.7% | 0.00% | – |
| Q3 2021 | $651,000 | +5.9% | 82,286 | +8.0% | 0.00% | – |
| Q2 2021 | $615,000 | -24.7% | 76,212 | +0.1% | 0.00% | – |
| Q1 2021 | $817,000 | +74.2% | 76,171 | +90.7% | 0.00% | – |
| Q4 2020 | $469,000 | +46.1% | 39,951 | +49.7% | 0.00% | – |
| Q3 2020 | $321,000 | -97.3% | 26,693 | -96.0% | 0.00% | -100.0% |
| Q2 2020 | $11,729,000 | – | 671,418 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ADAMS STREET PARTNERS LLC | 2,973,744 | $24,028,000 | 4.99% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,598,377 | $12,613,000 | 4.97% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,670,516 | $29,658,000 | 3.03% |
| Sio Capital Management, LLC | 266,107 | $2,150,000 | 0.53% |
| Orbimed Advisors | 3,224,770 | $26,056,000 | 0.26% |
| Perceptive Advisors | 3,550,334 | $28,686,000 | 0.19% |
| AlphaCentric Advisors LLC | 71,500 | $578,000 | 0.16% |
| Rock Springs Capital Management LP | 948,327 | $7,662,000 | 0.15% |
| TPG Group Holdings (SBS) Advisors, Inc. | 2,551,794 | $20,618,000 | 0.15% |
| Artal Group S.A. | 750,000 | $6,060,000 | 0.12% |